This Research Topic is part of a series with:
Genomic Discoveries and Pharmaceutical Development in Urologic TumorsUrologic tumors encompass cancers of the prostate, bladder, kidney, testis, and adrenal glands. Recent years have witnessed significant advancements in understanding the genomic landscape of urologic tumors, leading to the emergence of novel therapeutic strategies.
A particularly exciting area of research lies in genomic sequencing, enabling the identification of specific genetic mutations and biomarkers that can be targeted with drugs. For instance, drugs targeting the androgen receptor (AR) pathway, such as abiraterone and enzalutamide, have shown efficacy in treating prostate cancers with genetic alterations in this pathway. Additionally, drugs like sunitinib and pazopanib, which target the vascular endothelial growth factor (VEGF) pathway, have significantly improved survival rates for patients with metastatic renal cell carcinoma (RCC).
Another promising avenue of research focuses on repurposing drugs for tumor treatment. This approach offers a valuable means of discovering new cancer treatments by utilizing drugs already approved for other conditions and with known pharmacology. By doing so, researchers can reduce the time, cost, and risk associated with drug development while still providing effective therapies. For instance, beta-blockers, commonly used for high blood pressure and heart disease, have demonstrated potential in reducing the risk of cancer spread and improving survival in patients with prostate and bladder cancers.
Overall, genomic discoveries in urologic tumors have yielded fresh insights into the mechanisms of cancer progression, leading to the development of personalized therapies and new treatments. This Research Topic aims to gather articles that shed light on the interaction between genomics and pharmacology, driving new investigations into the mechanisms of urologic cancer and the development of innovative anti-cancer drugs.
We welcome submissions covering, but not limited to, the following areas:
• Preclinical studies: Investigate the safety and efficacy of potential drugs in animal models that mimic human urologic tumors, focusing specifically on genetic and molecular characteristics.
• Clinical trials: Conduct robust trials to evaluate the safety, efficacy, and optimal dosing of drugs for urologic tumors, utilizing genomic and molecular data to guide patient selection and treatment strategies.
• Artificial intelligence: Employ AI for genomic analysis to identify drug targets and optimize drug development processes, improving the speed and precision of discovering treatments for urologic cancers.
• Drug screening and in vivo studies: Screen compounds for activity against specific genetic targets in urologic tumors, followed by in vivo studies to assess their therapeutic potential and toxicity profiles.
• Modification of existing drugs: Enhance existing drug efficacy and safety through molecular modifications, combination therapies, or improved delivery methods tailored to the genetic profiles of urologic tumors.